The vaccine has an 86.3% efficacy against the B.1.1.7/501Y.V1 variant circulating in the U.K. Additionally, a phase IIB trial demonstrated a 55.4% efficacy against the COVID-19 South African variant, B.1.351, among the HIV-negative trial participants.

In both trials, NVX-CoV2373 demonstrated 100% protection against severe disease, including hospitalization and death.

The firm plans to use the data to serve as the basis for submission to various regulatory agencies worldwide authorizing the vaccine's use, Novavax said.

Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many...

Novavax to supply Covax with 1.1B COVID-19 vaccine doses
Novavax announced a memorandum of understanding with Gavi, the Vaccine Alliance, to provide 1.1 billion cumulative doses of its COVID-19 vaccine...

SK Bioscience to supply Novavax COVID-19 vaccine to millions in Korea
SK Bioscience is set to supply the Korean government with 40 million doses of Novavax's COVID-19 vaccine through a new collaboration and licensing...

Novavax begins several rolling regulatory reviews for its COVID-19 vaccine
Novavax has started the rolling review process for authorization of its COVID-19 vaccine, NVX-CoV2373, by multiple regulatory agencies.

Novavax to supply Switzerland with 6M doses of COVID-19 vaccine
Novavax has agreed to supply the country of Switzerland with 6 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.